Pioneering drug combination made available UK-wide
New combination of olaparib and bevacizumab means a leap forward in personalised treatments.
Read our latest updates from research breakthroughs to government actions to fundraising heroes.
New combination of olaparib and bevacizumab means a leap forward in personalised treatments.
Initial decision announced to make niraparib available from second line of treatment only to people with a BRCA1 or BRCA2 mutation.
Your donations will be matched pound for pound, up to £30,000!
We’re ending the postcode lottery in early diagnosis of ovarian cancer.
We welcome NHS England's landmark announcement to fund an ovarian cancer audit.
Our volunteers have been spreading the word, sharing stories and campaigning to raise awareness for Target Ovarian Cancer.
Research into screening for women with no symptoms of ovarian cancer concludes programme would not save lives.
Gamechanging drug could benefit thousands of women with advanced ovarian cancer every year.
Our gold-standard ovarian cancer research grants programme is open for 2021.
For Ovarian Cancer Awareness Month, Dr Alison Wint looks at why awareness and being involved in healthcare decisions is important.
We're urging women to take this key symptom seriously and go to the GP if they’re worried.
Double up to speed up early diagnosis with The Big Give Christmas Challenge 2020.
Sign up to receive emails and keep up to date on all things Target Ovarian Cancer
Sign up